Wikipedia -WSS

Wikipedia

author：fashion 2025-10-01 21:34:58 - browse：15765

STAT@ASCO 2024 — Chris Boshoff, far right, speaking at a panel with, from left, Matthew Herper of STAT, Ken Keller, Levi Garraway, and Susan Galbraith. Megan Bearder Photography

CHICAGO — The ways clinicians can treat cancers effectively are expanding, partly because technologies today are making old ideas possible, said a panel of oncology industry leaders at STAT@ASCO, STAT’s event here at the annual American Society of Clinical Oncology meeting.

“We’re seeing this expansion in modalities. We have more types of modalities that have arrived or arriving that allow us to exploit targets we’ve known about more than ever before. It’s very exciting,” said Levi Garraway, the chief medical officer of Genentech, at the event. “Things we’ve known about for a long time can be drugged for the first time or in a new, different way.”

That’s led to a surge of new medicines ranging from small molecules to cell therapies, with the potential uses of these treatments expanding into earlier lines of therapy and more cancer types each year. One example the panel singled out is the drug Enhertu, which recently received a tumor-agnostic approval from the Food and Drug Administration.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： In his State of the Union, Biden takes clear aim at 'Big Pharma'

hotspot

WSS

Novo Nordisk obesity pill bests Wegovy in early trial

CDC marks new Covid

Phenylephrine and the overlooked value of the placebo effect

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

What it’s like to watch children die of measles

Headspace, Meta partner to launch VR meditation app for Quest

explore

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Former medical device CEO who sold dummy, plastic parts convicted of fraud

After affirmative action ruling, medical educators look to 'holistic review'

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Medical records are filled with copy

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Cancer drug shortages should be causing more outrage

Sen. Paul opposes bill to ban Chinese biotechs

23andMe had bad news about my health. I wish a person had delivered it

How to bring more disabled researchers into academia

hotspot

UnitedHealth quietly bought dozens of outpatient centers

How to bring more disabled researchers into academia

With psoriasis trial ahead, Alumis raises $259 million

With psoriasis trial ahead, Alumis raises $259 million

Bill would stop addiction treatment from triggering child abuse inquiry

CDC marks new Covid

leisure time

hotspot

entertainment

hotspot